Skip to main content
    P

    Pliant Therapeutics Inc (PLRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.69
    -0.00 (-0.55%)

    Market Cap: $43.21M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pliant Therapeutics Inc (PLRX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Pliant Therapeutics (PLRX) to earn -$1.43 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 0 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Sell. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 3.50, inside the Sell band from 3.5 up to 4.5. Sell and Strong Sell make up 25% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold375.0%
    Sell00.0%
    Strong Sell125.0%
    Consensus
    Sell
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$1.43
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.28
    EPS consensus
    Next report
    Mar 9, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$1.43-$1.47 to -$1.413
    Dec 31, 2027-$1.28-$1.47 to -$0.943

    Quarterly Estimates

    The EPS consensus falls from -$0.38 for the quarter ending Dec 31, 2026 to -$0.39 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.38-$0.38 to -$0.386
    Mar 31, 2027-$0.39-$0.39 to -$0.391

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202622
    Fiscal year ending Dec 31, 202722
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.42.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.43-$1.46-$1.41-$1.41-$1.42N/A
    Fiscal year ending Dec 31, 2027-$1.28-$1.33-$0.81-$0.81-$1.03N/A
    Quarter ending Mar 31, 2027-$0.39-$0.39-$0.38-$0.38-$0.39N/A

    Frequently Asked Questions About PLRX

    What is the PLRX stock forecast?

    Consensus analyst estimates put Pliant Therapeutics's EPS at -$1.43 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Sell.

    How do analysts rate PLRX stock?

    Of 4 analysts covering Pliant Therapeutics, 0 rate it Strong Buy, 0 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Sell.

    What EPS do analysts expect from PLRX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.43, with estimates from -$1.47 to -$1.41 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.28, with estimates from -$1.47 to -$0.94 from 3 analysts.

    How many analysts cover PLRX?

    4 analysts rate Pliant Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.